Can NVST Sustain Its 2026 Guidance Boost as Margins Keep Expanding?

NVST’s Raised Guidance Resets 2026 Expectations

Management lifted its 2026 core sales growth forecast to 3.5%-4.5% from 2%-4%. Adjusted EBITDA is now expected to grow 11%-14%, while adjusted earnings are projected at $1.50-$1.55 per share.

The free-cash-flow conversion target remains approximately 100% of adjusted net income. The Zacks Consensus Estimate stands at $1.53 per share for 2026, placing the consensus mark near the midpoint of management’s revised range.

Image Source: Zacks Investment Research

Envista’s Q2 Results Back the Higher Outlook

Second-quarter revenues increased 7.1% year over year to $730.5 million, while core sales advanced 5%. First-half core growth was just over 7%, giving Envista a stronger base heading into the second half.

Equipment & Consumables led the quarter with 8.5% core sales growth, supported by high-single-digit gains in consumables and diagnostics. Align Technology, Inc. ALGN also reported 8.2% year-over-year growth in second-quarter clear aligner revenues, while DENTSPLY SIRONA Inc. XRAY reported $898 million in quarterly net sales and reiterated its 2026 outlook, offering useful context for demand and execution across dental markets.

NVST’s Margin Gains Raise the Earnings Ceiling

Adjusted gross margin expanded 70 basis points year over year in the second quarter. Adjusted EBITDA margin rose 230 basis points to 14.7%, helping adjusted EBITDA increase 28% despite continued investment in sales, marketing and research and development.

Envista credited manufacturing productivity, pricing, volume and foreign exchange for part of the improvement. The Envista Business System also supported operating leverage, while productivity measures more than offset input-cost inflation and higher tariff costs.

Envista Faces China VBP and Tariff Pressure

China’s volume-based procurement programs remain a key second-half variable. Management expects the orthodontic program to result in a large price reduction, similar to the roughly 45% decline seen during the first implant program, while the second implant program could reduce prices by about 10%-15%.

Tariff costs increased about $5 million year over year in the second quarter and are expected to remain at similar quarterly levels in the second half. Management has incorporated both China volume-based procurement programs into guidance, but these headwinds leave less room for operational slippage.

NVST’s Strong Signals Support the Guidance Reset

The raised outlook is supported by better sales momentum, wider margins and higher earnings expectations, but sustaining the reset will depend on Envista carrying those gains through a more challenging second half. The company expects fourth-quarter core growth to be flat to slightly down because of four fewer selling days, though growth excluding that calendar effect is expected to align with the full-year range.

NVST currently carries a Zacks Rank #1 (Strong Buy). It also has a Value Score of B, Momentum Score of B and VGM Score of B, a combination that complements the top Zacks Rank. The Growth Score of D is less favorable, keeping attention on whether the 2026 earnings rebound can translate into a more durable growth profile.

You can see the complete list of today's Zacks #1 Rank stocks here.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research